Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Currency in USD	2025
Operating Income	7.75 Billion
Income Before Tax	7.31 Billion
Income Tax Expense	547.00 Million
Net Income	6.70 Billion
Eps	17.77
Epsdiluted	17.74
Weighted Average Shs Out	377.00 Million
Weighted Average Shs Out Dil	378.00 Million
Research And Development Expenses	1.40 Billion
Selling General And Administrative Expenses	8.73 Billion
Depreciation And Amortization	2.78 Billion
Interest Expense	1.42 Billion
Interest Income	993.00 Million
Net Interest Income	-426 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	18.24 Billion
Ebitda	10.89 Billion
Source	edgar
Ebit	8.73 Billion

Thermo Fisher Scientific Inc. Annual Reports (10-K)